心力衰竭治疗药物新进展  

New advances in the drugs used in the treatment of heart failure

作　　者：刘莹[1] 高宇 LIU Ying;GAO Yu(The First Affiliated Hospital of Harbin Medical University,Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属第一医院,黑龙江哈尔滨150000

出　　处：《实用药物与临床》2021年第12期1137-1140,共4页Practical Pharmacy and Clinical Remedies

基　　金：黑龙江省卫生厅资助项目(2019-030)。

摘　　要：心力衰竭是各种心脏疾病的最终阶段,也是心血管疾病的主要死因。近年来根据不同心衰发病机制研发的针对不同靶点治疗心衰的新药问世,使心衰患者的临床症状得以缓解,预期寿命延长,同时也为临床医生在治疗方案上提供了更多选择。本文将对治疗心衰的3种最新药物(沙库巴曲缬沙坦、维利西呱、达格列净)进行综述。Heart failure is the final stage of all kinds of heart diseases and the main cause of death of cardiovascular diseases.In recent years, according to different pathogenesis of heart failure, new drugs have been developed to treat heart failure with different targets.New drugs have been developed to help patients with heart failure improve their clinical symptoms and extend their life expectancy;it also provides clinicians with more choices for treatment options.In this paper, three new drugs(Sacubitril/valsartan, Vericiguat, and Dapagliflozin) for the treatment of heart failure are reviewed.

关 键 词：血管紧张素受体-脑啡肽酶抑制剂 沙库巴曲缬沙坦 维利西呱 钠-葡萄糖协同转运蛋白2 达格列净 

分 类 号：R972[医药卫生—药品]